Wells Fargo initiated coverage of Arcellx (ACLX) with an Overweight rating and $100 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX:
- Positive Outlook for Arcellx Inc: Buy Rating Backed by Strategic Positioning and Promising CAR T-cell Therapy
- Arcellx Reports Promising Phase 2 Study Results
- Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Arcellx Inc
- Arcellx Inc’s Promising Future: Buy Rating Backed by Strong Efficacy, Safety, and Strategic Partnerships
- Arcellx Inc’s Anito-cel: Promising CAR-T Therapy with Superior Safety Profile and Market Readiness